Update April 23, 2019 – Orphazyme A/S announced that its Phase II/III trial of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM) is fully enrolled.
“The study is a 20-month trial comparing placebo with active treatment (arimoclomol) with a planned interim analysis at 12 months. However, it is not anticipated that the study will end at this time. The final study results are expected in the first half of 2021 at the conclusion of the 20-month timepoint. The 20-month primary analysis time-point was established with regulatory authorities (FDA and EMA) to maximize chances of success, potentially allowing for a meaningful difference to be seen between participants receiving active treatment vs placebo.”
Performance of interim analysis and study completion expected in H1 2020 and by end 2020, respectively. Results are expected in H1 2021.
“Our team looks forward to continued conversations with The Myositis Association (TMA), Myositis Support & Understanding (MSU), the Muscular Dystrophy Association (MDA), those participating in the Yale IBM Registry, and other patient organizations to ensure the latest information regarding Orphazyme’s clinical development program in sIBM is available to those who need it most: People living with sIBM and their loved ones.”
The Phase II/III trial of arimoclomol for sIBM is a 150-patient, 20-month, randomized, double-blinded, placebo-controlled trial at 11 centers of excellence in the US and one in the UK. Orphazyme has initiated an open-label extension trial to which patients from the Phase II/III trial may enroll and continue treatment.
As part of our mission at Myositis Support and Understanding Association (MSU), we are constantly looking for ways to advocate for you, the Myositis Community, by engaging with research and pharmaceutical companies to better the lives of patients and caregivers. One of our goals is to provide you with access to research.
To this end, MSU is excited to announce a new relationship with Orphazyme, the Danish biopharmaceutical company sponsoring the Arimoclomol Phase II/III clinical trial for sporadic inclusion body myositis (sIBM).
In a series of conference calls with Regan Sherman, Associate Director of Patient Advocacy Relations, we discussed the various ways Orphazyme and MSU can work together to benefit those living with sporadic inclusion body myositis. These talks were very productive and we look forward to realizing many of the ideas and events discussed.
As a part of our relationship, we will bring information and updates directly to the sIBM patient and caregiver communities. We will also work together with Orphazyme to help guide education, awareness, outreach, and other efforts valuable to our membership.
“This is an exciting mutually beneficial relationship with a shared goal of a successful clinical trial and ultimately, a treatment for sIBM patients,” says Jerry Williams, Founder and President of Myositis Support and Understanding Association.
Many patients are interested in the arimoclomol trial and with good reason. Sporadic inclusion body myositis (sIBM) is a rare, disabling inflammatory and muscle-wasting disease, one of several in the group of muscle diseases called the Idiopathic Inflammatory Myopathies. There are currently no available treatment options for patients with sIBM. Rather, patients are usually directed to utilize exercise to help slow disease progression by maintaining muscle strength and to make life adaptations, or life hacks, to better live with this disabling disease.
Further clinical trial summary information can be found on the Pipeline tab on the Orphazyme website.
We thank Regan and the entire Orphazyme team for their willingness to work with and learn from myositis nonprofits and community organizations. We also thank the inclusion body myositis community for their strength, patience, and excitement as we continue to work for them.
As with any relationship MSU enter into with pharmaceutical companies, our policies will not be determined or guided by any contributions, financial or otherwise. Member privacy is always protected and members private information is never shared with any third parties unless expressly consented, including informed and signed consent.
Arimoclomol is a new chemical entity with a very favorable safety and tolerability record in humans: Seven Phase I clinical studies have been conducted in healthy volunteers. Arimoclomol is administered orally, three times daily, and can be easily dissolved in liquids or food for best possible patient comfort and compliance. Orphazyme has obtained orphan drug designation for arimoclomol in NPC, ALS, and sIBM from both the FDA and EMA.
About Orphazyme A/S
Orphazyme is a Danish biotech company listed on Nasdaq Copenhagen with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases. The company was founded in 2009 based on early scientific discovery in heat-shock proteins. The company is headquartered in Copenhagen and currently has 30 employees. The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis (“sIBM”) and Amyotrophic Lateral Sclerosis (“ALS”), and two lysosomal storage diseases, Niemann Pick Type C (“NPC”) and Gaucher disease. For more information, please visit www.orphazyme.com.Tags: arimoclomolclinical trialsinclusion body myositis